Peyronie's Disease
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
2
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
UNION therapeuticsDenmark - Hellerup
2 programs2
CCH administrationPhase 41 trial
Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex]Phase 41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
UNION therapeuticsCCH administration
UNION therapeuticsCollagenase Clostridium Histolyticum 0.9 MG [Xiaflex]
AbbVie100 units of Botulinum Toxin Type A
Clinical Trials (3)
Total enrollment: 92 patients across 3 trials
Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders
Start: Sep 2021Est. completion: Sep 202840 patients
Phase 4Active Not Recruiting
Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's
Start: Dec 2020Est. completion: Feb 202740 patients
Phase 4Active Not Recruiting
H-22411: BOTOX® for Peyronie's Disease
Start: Aug 2009Est. completion: Jan 201912 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.